NEW YORK, USA // Kerry Ciociola doesn’t believe in advertising. She believes in problem solving.

In the beginning, she spent many grueling hours finding creative ways to showcase the differences in Cabot Cheese’s products over their competitors. In her creative research, she found a passion for finding new ways of making the human experience better, one dairy product at a time.

However, after a few years of cheddar, cars, banks, and airlines, Kerry was beginning to itch for bigger problems to solve, more important issues than interest rates and airline upgrades, so she turned to the world of healthcare.

Over the past 19 years, Kerry has had the opportunity to work across a broad range of indications for professional and consumer audiences, both in the United States and globally. She has worked on blockbuster drugs such as Nexium, Spiriva, Pradaxa, Gilenya, and Repatha–launching new indications and campaigns that have moved the needle from a business standpoint, as well as garnered attention in high-profile award shows such as The Clios, One Show, and Cannes.

Kerry had been spending most of her time helping patients with multiple sclerosis learn to live well, empowering and educating parents of infants with spinal muscular atrophy, and providing sufferers of alopecia areata something they’ve never had before: a treatment. Her latest endeavor has been in the world of type two diabetes and weight management, with the launch of Lilly’s Mounjaro and Zepbound. Heralded as one of the most successful drug launches in pharmaceutical history, she has gotten to witness what healthcare can truly do on a global level.

As someone living with a chronic disease, Kerry has learned firsthand what knowledge can do for a health journey. This is why the work we do matters. The past few years at FCB Health (as well as her history with the company), have proven that the commitment to making meaningful work that matters is out there, and worth celebrating.